ACAD
ACADIA Pharmaceuticals (ACAD) Stock Valuation
Review ACADIA Pharmaceuticals (ACAD) valuation with server-rendered company data, supporting context and links to related investor research.
- Price to earnings
- 13.07
- Price to book
- 3.68
- Dividend yield
- 0%
- Return on equity
- 0%
- BTI fair market cap
- $7.88B
- Premium or discount
- -37.93%
- Market cap
- $4.89B
ACADIA Pharmaceuticals (ACAD) Stock Valuation research
The ACADIA Pharmaceuticals valuation page presents the available multiples, profitability measures and BTI fair-value context for ACAD. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.